Sichuan Kelun Pharmaceutical Co Ltd 2022 SR
The report highlights Kelun Pharma's 2022 ESG performance, focusing on its innovation-driven strategy with 1.815 billion RMB invested in R&D. Key achievements include the establishment of an ESG Committee and the successful collaboration with Merck Sharp & Dohme on ADC projects valued at nearly US$11.8 billion. The company maintained a 100% passing rate for product sampling inspections and achieved significant progress in green manufacturing, with several subsidiaries receiving ISO 14001 and ISO 50001 certifications. Socially, the company supported rural revitalization and public welfare with over 70 million RMB in donations.
Company: Sichuan Kelun Pharmaceutical Co Ltd
Sector: Health Care
Country: China
Year: 2022
Type: SR
Pages: 76
Sichuan Kelun Pharmaceutical Co Ltd
ESG Report
The report highlights Kelun Pharma's 2022 ESG performance, focusing on its innovation-driven strategy with 1.815 billion RMB invested in R&D. Key achievements include the establishment of an ESG Committee and the successful collaboration with Merck Sharp & Dohme on ADC projects valued at nearly US$11.8 billion. The company maintained a 100% passing rate for product sampling inspections and achieved significant progress in green manufacturing, with several subsidiaries receiving ISO 14001 and ISO 50001 certifications. Socially, the company supported rural revitalization and public welfare with over 70 million RMB in donations.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Published
Apr 12, 2023
Type
Sustainability Report
Language
English, Chinese
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women in Management
Employees